Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 6,816 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,816 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $93.13, for a total transaction of $634,774.08. Following the transaction, the chief executive officer now owns 227,710 shares in the company, valued at approximately $21,206,632.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The shares were sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $964,178.17.
• On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The shares were sold at an average price of $68.16, for a total transaction of $133,457.28.

Natera Trading Up 0.0 %

NASDAQ NTRA opened at $90.33 on Thursday. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The company has a fifty day moving average price of $85.39 and a 200-day moving average price of $65.41.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. As a group, sell-side analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Trading of Natera

A number of large investors have recently added to or reduced their stakes in the stock. Tlwm purchased a new stake in Natera during the first quarter worth about $264,000. Wealth Enhancement Advisory Services LLC increased its holdings in Natera by 25.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock worth $528,000 after buying an additional 1,155 shares during the last quarter. Park Avenue Securities LLC increased its holdings in Natera by 17.5% during the first quarter. Park Avenue Securities LLC now owns 5,368 shares of the medical research company’s stock worth $491,000 after buying an additional 799 shares during the last quarter. Banque Cantonale Vaudoise increased its holdings in Natera by 6.6% during the first quarter. Banque Cantonale Vaudoise now owns 7,235 shares of the medical research company’s stock worth $662,000 after buying an additional 451 shares during the last quarter. Finally, Fulton Bank N.A. purchased a new stake in Natera during the first quarter worth about $251,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of research reports. Canaccord Genuity Group boosted their target price on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, March 14th. Raymond James lowered shares of Natera from a “strong-buy” rating to an “outperform” rating and boosted their price target for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Stephens restated an “overweight” rating and set a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. Finally, The Goldman Sachs Group boosted their price target on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.